Business Wire

Strategic Minority Investment Company MiNA Therapeutics Enters Into Collaboration and Licensing Agreement With Boehringer Ingelheim

Jaa

Sosei Group Corporation (‘Sosei’; TSE Mothers Index 4565), is pleased to note that our strategic minority investment company MiNA Therapeutics ('MiNA') has announced a collaboration and licensing agreement with the global pharmaceutical company Boehringer Ingelheim for the development of novel treatment approaches for fibrotic liver diseases.

Under the terms of the agreement, MiNA will receive an upfront payment and committed research funding as well as potential research, development and regulatory milestone payments totaling up to EUR 307 million. In addition, MiNA is entitled to double-digit royalties on sales of selected products resulting from the partnership. No further financial details were disclosed.

Commenting on the release, Peter Bains, CEO at Sosei, said: “We are very encouraged by this agreement, which is MiNA’s first ever major collaboration and reinforces its leading position in small activating RNA (‘saRNA’) therapeutics. Furthermore, we believe it represents a strong validation of the broad potential for its proprietary technology.”

Click here for link to the full press release from MiNA Therapeutics and Boehringer Ingelheim

About Sosei Group Corporation

Sosei Group Corporation is an international biopharmaceutical company originating from Japan that discovers and develops innovative biopharmaceuticals for the treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. By utilizing its GPCR structure-based drug design platform technology, Sosei has established a product pipeline with first/best in class potential. Through development and commercialization partnerships, Sosei has already delivered two bronchodilators for COPD which generate significant and stable revenue streams that enable further growth. Sosei partners include Novartis, Allergan, AstraZeneca, MedImmune, MorphoSys, Teva, and Pfizer and we are actively looking for new partnerships to enhance the development of our products and help us deliver them to patients worldwide.

For further information about Sosei, please visit http://www.sosei.com/en/.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact information

Sosei Group Corporation
Chris Cargill, +44-(0)7912-892-199
Head of Investor Relations and Corporate Communications
ccargill@sosei.com
or
Harumi Banse, +81-(0)3-5210-3399
Investor Relations and Corporate Communications
hbanse@sosei.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

CORRECTING and REPLACING "Complete Your Game!"The 13th Global Game Exhibition G-STAR 2017 Opens to Success21.11.2017 13:10Tiedote

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120006218/en/ Opening Ceremony of G-STAR 2017 (Photo: Business Wire) The corrected release reads: "COMPLETE YOUR GAME!" THE 13TH GLOBAL GAME EXHIBITION G-STAR 2017 OPENS TO SUCCESS The exhibition reached record success featuring 2,857 booths by 676 companies from 35 countries It showcases an array of newly released games of various genres and scales The start of the G-STAR Game Show and Trade All Round 2017, an international game exhibition that examines the global gaming industry and its future possibilities, was announced at BEXCO, Busan, on Nove

Telstra and Sigma Systems to Present Catalog-Driven Dynamic Offer Creation at TM Forum Live! Asia21.11.2017 13:00Tiedote

Sigma Systems, the global leader in catalog-driven software, announced today that it will be presenting at TM Forum Live! Asia in partnership with Telstra, Australia’s leading telecommunications and technology company. Sigma’s Chief Technology Officer (CTO), Catherine Michel, will be on stage with Telstra's Chief Technology Officer (Customer), Dr. Fawad Nazir, to discuss why traditional service providers must adopt a “digital native” mindset and the corresponding operational agility to thrive in a digital economy. The ability to create and launch new offers in minutes, rather than months, and rapidly enable new business models is critical to an operator’s success. “Sigma Catalog creates the ability to sell through and then orchestrate the fulfillment of an order from different channels into the full B/OSS stack and across various delivery networks. The product’s Offer Canvas

Seoul Semiconductor First in the World to Receive Low Risk Eye Safety Certification for its Natural Light LED SunLike21.11.2017 12:00Tiedote

The world-leading LED company Seoul Semiconductor (Head office: Ansan-si, Korea, CEO: Chung Hoon Lee, hereinafter Seoul Semiconductor) announced that SunLike, which implements light which comes closest to sunlight, received an RG-1 Eye Safety certification based on the safety of its light source and was recognized for the highest level of safety amongst 25W COB type LED. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005036/en/ 25W SunLike light source which acquired RG-1 grade in Eye Safety certification (Photo: Business Wire) Eye Safety certification is a rating based on safety from analyzing the LED wavelengths. In Europe, where top priority is placed on the safety of lighting, Eye Safety certification is essential and the light source must be higher than RG-3 level, otherwise eye sight may b

FlexTrade Introduces Enhanced Cross-OMS Aggregation for MiFID II21.11.2017 12:00Tiedote

FlexTrade Systems (@FlexTrade), a global leader in cross-asset execution and order management systems, today announced the rollout of an enhanced version of its multi-OMS aggregation functionality, an in-built feature of the FlexTRADER EMS, which allows users to merge and net orders across multiple OMSs regardless of the underlying version or implementation. “With a number of major asset manager mergers over the past few years bringing together a variety of OMS technologies, we have seen a surge of interest in FlexTRADER’s unique abilities in cross-OMS order aggregation,” said Oliver Boatfield, EMEA Sales Director at FlexTrade UK. Along with the ability to dynamically merge orders within and across OMSs, FlexTRADER provides highly configurable allocation logic with several out-of-the-box rules, including LIFO, FIFO, pro-rata and optimal average pricing. I

Starr Companies Announces Aviation Insurance Agreement with SMARTT MGA21.11.2017 11:00Tiedote

Starr Companies today announced an agreement with SMARTT MGA to act as Agents for Starr International (Europe) Limited to provide automated quotes and policy documentation for light general aviation business. “We have built a close and fruitful relationship with SMARTT and are happy that we have formalized this arrangement,” stated Jim Herbert, chief underwriting officer, aviation. “We believe our StarrLink International platform will bring significant efficiencies to the way aviation business is placed. We look forward to expanding our product offerings through SMARTT MGA in the near future.” Michal Chmielewski, chief executive officer, SMARTT MGA, stated, “Most quotes, binding and policy documentation issuance take only a few minutes to produce through the StarrLink platform – changing the way aviation insurance is purchased.” SMARTT MGA is a part of SMARTT Grou

Octapharma Donates 30.5 Million International Units of Its Medicine Nuwiq to Treat People with Haemophilia in Developing Countries21.11.2017 11:00Tiedote

2017: Octapharma is pleased to announce the completion of a charitable donation of 30.5 million international units of its human cell-line derived recombinant factor VIII product, Nuwiq®, in collaboration with Project SHARE, North Andover, Massachusetts (USA). This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005038/en/ Donation in Nepal of human cell-line derived recombinant factor VIII product Nuwiq (Photo: Business Wire) Up to 75% of the world's estimated 400,000 people with haemophilia have little or no access to treatment that resolves life- and limb-threatening bleeds, and enables surgery and rehabilitation. A humanitarian program, Project SHARE facilitates the donation of blood-clotting factor products for the treatment of people with haemophilia in need of factor replacement therapy

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme